Skip to main content
Clinical Trials/CTIS2023-506512-40-00
CTIS2023-506512-40-00
Active, not recruiting
Phase 1

Effect of low-dose arginine-vasopressin supplementation on post-transplant Acute Kidney Injury after liver transplantation - AVENIR Trial - APHP220827

Assistance Publique Hopitaux De Paris0 sites304 target enrollmentOctober 2, 2023

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Acute Kidney Injury, Liver transplantation
Sponsor
Assistance Publique Hopitaux De Paris
Enrollment
304
Status
Active, not recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 2, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age \= 18 years, Any adult patient with a scheduled liver transplantation, All participants will need to be given clear information about the study and give signed informed consent, Person affiliated to the Social Security

Exclusion Criteria

  • Super\-emergency for liver transplantation or fulminant hepatitis, Pregnancy or breastfeeding, Patient listed for or receiving simultaneous liver\-kidney transplantation (SLKT), Patients with end\-stage renal disease (chronic eGFR \< 15 mL/min/1\.73 m2 or requiring extra\-renal purification before liver transplantation, Patient with epilepsy, Hypersensitivity to arginine\-vasopressin and to its excipients, Patient refusal, Patients for whom it is impossible to give informed consent (language barrier), Adults under guardianship or trusteeship, persons deprived of their liberty, Patient enrolled in another interventional clinical study

Outcomes

Primary Outcomes

Not specified

Similar Trials